OBR Daily Commentary

forumImage

Antimalarial Drug Touted By President Trump Is Linked To Increased Risk Of Death In Coronavirus Patients, Study Says

(Washington Post) May 23, 2020 - A study of 96,000 hospitalized coronavirus patients on six continents found that those who received an antimalarial drug promoted by President Trump as a “game changer” in the fight against the virus had a significantly higher risk of death compared with those who did not.

Victoria Villaflor (Posted: May 26, 2020)

quotesThis is truly a sad day when we let politics get in the way of science. The studies done to date are in ill patients who were hospitalized and at greater risk of death, this article comments on the ethics of doing a study which evaluates the question in patients who are at home and hence, healthier. As a scientist and physician, what I would like to know is the following: 1.) Time to clear virus 2.) Recovery time from symptoms 3.) number of hospitalizations 4.) Number of patients requiring ventilator support 5.) Number of deaths in each group. Hydroxychloraquine is a safe drug not only have many of my patients taken it for lupus and other autoimmune diseases, I have taken it as malaria prophylaxis. Scientifically, by reduction of inflammation may reduce risk of ARDS due to cytokine storm. I am a non-partisan person and don't care one way or another about politics. To allow this type of garbage into our scientific rigors truly marks a sad day! It appears as this drug is being judged based on ones like or dislike for the president. Stop this childish rhetoric and let the science speak for itself.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

U.S. FDA Approves Takeda’s ALUNBRIG® (brigatinib) as a First-Line Treatment Option for Patients Diagnosed with Rare and Serious Form of Lung Cancer

(Takeda) May 22, 2020 - Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) approved ALUNBRIG (brigatinib) for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test. This approval expands ALUNBRIG’s current indication to include the first-line setting. ALUNBRIG is a potent and selective next-generation tyrosine kinase inhibitor (TKI) designed to target ALK molecular alterations.

H. Jack West, MD (Posted: May 26, 2020)

quotesAnother option in the first line setting for patients with advanced ALK+ NSCLC, though brigatinib ended up with overall survival results that appear no better and even numerically inferior to what we've seen with alectinib. Accordingly, I don't think there's reason to expect brigatinib should displace alectinib as the prevailing favored standard of care in this setting.quotes

Read Article arrow
Add Comment 1 Comment
forumImage

Low-dose Erlotinib Effective In Frail Patients, Early Trial Suggests

(Reuters Health) May 21, 2020 - Low-dose erlotinib is safe and effective in elderly or frail patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer (NSCLC), a new single-arm phase-2 trial suggests.

H. Jack West, MD (Posted: May 24, 2020)

quotesElderly or frail patients did just as well on a reduced dose of erlotinib, with fewer adverse effects. Nice to have some prospective data on a question we've been asking and sometimes empirically managing differently based on our inferences for over a decade. quotes

Read Article arrow
Add Comment 1 Comment

Meet the Editorial Board

Prostate Cancer
member photo
Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical O...

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Associate Clinical Professor, Medical Oncology Executi...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Woo...

Radiation Oncology
member photo
Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics
Pr...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

member photo
Stephen M. Schleicher, M.D., MBA

Community Oncology, Medical Oncologist, OneOncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...